These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

342 related items for PubMed ID: 28116656

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Solid lipid nanoparticles as vesicles for oral delivery of olmesartan medoxomil: formulation, optimization and in vivo evaluation.
    Nooli M, Chella N, Kulhari H, Shastri NR, Sistla R.
    Drug Dev Ind Pharm; 2017 Apr; 43(4):611-617. PubMed ID: 28005442
    [Abstract] [Full Text] [Related]

  • 3. In Vitro and In Vivo Evaluation of Olmesartan Medoxomil Microcrysta ls and Nanocrystals: Preparation, Characterization, and Pharmacokinet ic Comparison in Beagle Dogs.
    Chai R, Gao H, Ma Z, Guo M, Fu Q, Liu H, He Z.
    Curr Drug Deliv; 2019 Apr; 16(6):500-510. PubMed ID: 31244438
    [Abstract] [Full Text] [Related]

  • 4. Development of surface stabilized candesartan cilexetil nanocrystals with enhanced dissolution rate, permeation rate across CaCo-2, and oral bioavailability.
    Jain S, Reddy VA, Arora S, Patel K.
    Drug Deliv Transl Res; 2016 Oct; 6(5):498-510. PubMed ID: 27129488
    [Abstract] [Full Text] [Related]

  • 5. Nanostructured lipid carriers of olmesartan medoxomil with enhanced oral bioavailability.
    Kaithwas V, Dora CP, Kushwah V, Jain S.
    Colloids Surf B Biointerfaces; 2017 Jun 01; 154():10-20. PubMed ID: 28284054
    [Abstract] [Full Text] [Related]

  • 6. Development of olmesartan medoxomil optimized nanosuspension using the Box-Behnken design to improve oral bioavailability.
    Nagaraj K, Narendar D, Kishan V.
    Drug Dev Ind Pharm; 2017 Jul 01; 43(7):1186-1196. PubMed ID: 28271908
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Development of an amorphous nanosuspension by sonoprecipitation-formulation and process optimization using design of experiment methodology.
    Gajera BY, Shah DA, Dave RH.
    Int J Pharm; 2019 Mar 25; 559():348-359. PubMed ID: 30721724
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Use of transethosomes for enhancing the transdermal delivery of olmesartan medoxomil: in vitro, ex vivo, and in vivo evaluation.
    Albash R, Abdelbary AA, Refai H, El-Nabarawi MA.
    Int J Nanomedicine; 2019 Mar 25; 14():1953-1968. PubMed ID: 30936696
    [Abstract] [Full Text] [Related]

  • 17. Development of megestrol acetate solid dispersion nanoparticles for enhanced oral delivery by using a supercritical antisolvent process.
    Ha ES, Kim JS, Baek IH, Yoo JW, Jung Y, Moon HR, Kim MS.
    Drug Des Devel Ther; 2015 Mar 25; 9():4269-77. PubMed ID: 26345723
    [Abstract] [Full Text] [Related]

  • 18. Product development studies on surface-adsorbed nanoemulsion of olmesartan medoxomil as a capsular dosage form.
    Singh S, Pathak K, Bali V.
    AAPS PharmSciTech; 2012 Dec 25; 13(4):1212-21. PubMed ID: 22965661
    [Abstract] [Full Text] [Related]

  • 19. Enhance the dissolution rate and oral bioavailability of pranlukast by preparing nanosuspensions with high-pressure homogenizing method.
    Wang L, Hao Y, Liu N, Ma M, Yin Z, Zhang X.
    Drug Dev Ind Pharm; 2012 Nov 25; 38(11):1381-9. PubMed ID: 22300415
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.